Table 1.
Patient characteristics
| Overall population (n = 1,169) | |
|---|---|
| Age, median (IQR) | 69.7 (60.9–75.9) |
| Gender, n (%) | |
| Male | 820 (70.2) |
| Female | 349 (29.9) |
| ECOG PS, n (%) | |
| 0 | 678 (58.0) |
| 1 | 419 (35.8) |
| 2 | 53 (4.5) |
| 3 | 3 (0.3) |
| Unknown | 16 (1.4) |
| Primary tumor, n (%) | |
| Lung | 635 (54.3) |
| RCC | 200 (17.1) |
| Melanoma | 150 (12.8) |
| UC | 65 (5.6) |
| H&N | 45 (3.9) |
| Other | 74 (6.3) |
| ICI treatment line, n (%) | |
| 1 | 582 (49.9) |
| 2 | 482 (41.3) |
| 3 | 101 (8.7) |
| Unknown | 4 (0.1) |
| Therapy, n (%) | |
| ICI/ICI+ICI | 1,097 (93.8) |
| ICI + othera | 72 (6.2) |
| Smoking habits, n (%) | |
| Current | 281 (24.0) |
| Former | 509 (43.5) |
| Never | 348 (29.8) |
| Unknown | 31 (2.7) |
| Bone metastases, n (%) | 349 (29.9) |
| Brain metastases, n (%) | 181 (15.5) |
| Liver metastases, n (%) | 149 (12.8) |
| Pre-treatment steroids, n (%) | 337 (28.8) |
| Neutrophils, median (IQR) | 4.9 (3.6–7.1) |
| Lymphocyte, median (IQR) | 1.61 (1.16–2.25) |
| Platelets, median (IQR) | 255.3 (200–322) |
| NLR, median (IQR) | 3.3 (2.2–4.9) |
| dNLR, median (IQR) | 1.92 (1.43–2.54) |
| SII, median (IQR) | 829.2 (506.7–1,451.4) |
| LDH, median (IQR) | 390 (217–581) |
dNLR, derived neutrophil-to-lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; H&N, head and neck; ICI, immune checkpoint inhibitor; IQR, interquartile range; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; n, number; PS, performance status; RCC, renal cell carcinoma; SII, systemic immune-inflammatory index; UC, urothelial carcinoma.
a
Chemotherapy or targeted therapy.